2
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Melanoma
22
Carcinoma, Renal Cell
19
HIV Infections
6
Acquired Immunodeficiency Syndrome
6
Sarcoma, Kaposi
5
Leukemia
5
Neoplasm Metastasis
4
Lymphoma
4
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
4
Triple Negative Breast Neoplasms
3
Recurrence
3
Neoplasms
3
Kidney Neoplasms
3
Hematologic Neoplasms
3
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Pancreatic Neoplasms
2
Mycosis Fungoides
2
Multiple Myeloma
2
Leukemia, Myeloid, Chronic-Phase
2
Colorectal Neoplasms
2
Breast Neoplasms
2
Brain Neoplasms
2
Uveal Melanoma
1
Uterine Cervical Neoplasms
1
Uterine Cervical Dysplasia
1
Urinary Bladder Neoplasms
1
Urethral Neoplasms
1
Tumor Virus Infections
1
Thrombocythemia, Essential
1
Solid Cancers
1
Interventions
Paclitaxel
4
liposomal doxorubicin
3
Carboplatin
3
pembrolizumab
2
Bevacizumab
2
1-dodecylpyridoxal
2
poly(I).poly(c12,U)
1
mirabegron
1
disitamab vedotin
1
apatinib
1
anlotinib
1
Tocotrienols
1
Platinum Compounds
1
Lenalidomide
1
Interferon alpha-2
1
Hyperthermic Intraperitoneal Chemotherapy
1
Gemcitabine
1
EP-100 membrane-disrupting peptide
1
Cisplatin
1
AC 7700
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Ovarian Cancer Recurrent
×
Interferon alpha-2
×
Clear all
NCT04072263
2021-04-01
OVACURE
Leiden University Medical Center
Phase 1/2
Unknown
12 enrolled